HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Intraocular lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that primarily affects the eyes. This condition involves the infiltration of malignant lymphocytes, a type of white blood cell, into the intraocular structures, including the vitreous humor and retina. In most cases, intraocular lymphoma is a manifestation of primary central nervous system lymphoma (PCNSL), where the disease originates in the brain and spreads to the eyes. Symptoms of intraocular lymphoma often include blurred vision, floaters, and, in some cases, eye pain. Due to the nonspecific nature of these symptoms, diagnosis can be challenging and may require a comprehensive eye examination, imaging studies, and biopsy of ocular tissues. The management of intraocular lymphoma typically involves a multidisciplinary approach, including collaboration between ophthalmologists, oncologists, and other specialists. Treatment options may include chemotherapy, radiation therapy, or a combination of both, tailored to the individual patient's condition. Prognosis for intraocular lymphoma varies, and outcomes can be influenced by factors such as the extent of ocular involvement, response to treatment, and the presence of systemic disease. Given the rarity and complexity of intraocular lymphoma, ongoing research is essential to further understand its underlying mechanisms and develop more effective therapeutic strategies. Regular monitoring and follow-up care are crucial for managing this challenging condition and optimizing the quality of life for affected individuals.
